ATNM
AMEX · Biotechnology
Actinium Pharmaceuticals Inc
$1.18
-0.02 (-1.67%)
Financial Highlights (FY 2026)
Revenue
90.4K
Net Income
-33,870,209
Gross Margin
—
Profit Margin
-37,652.2%
Rev Growth
-55.6%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 53.0% | 53.0% |
| Operating Margin | -40,274.4% | -36,247.1% | -29.8% | -25.4% |
| Profit Margin | -37,652.2% | -35,769.6% | -23.9% | -19.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 90.4K | 203.8K | 4.99M | 5.52M |
| Gross Profit | — | — | 2.65M | 2.93M |
| Operating Income | -36,416,148 | -73,866,425 | -1,486,150 | -1,401,985 |
| Net Income | -33,870,209 | -68,702,249 | -1,193,914 | -1,096,791 |
| Gross Margin | — | — | 53.0% | 53.0% |
| Operating Margin | -40,274.4% | -36,247.1% | -29.8% | -25.4% |
| Profit Margin | -37,652.2% | -35,769.6% | -23.9% | -19.9% |
| Rev Growth | -55.6% | -55.6% | +20.9% | +5.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 26.2K | 26.2K | 13.17M | 13.40M |
| Total Equity | 18.68M | 18.68M | 19.58M | 16.67M |
| D/E Ratio | 0.00 | 0.00 | 0.67 | 0.80 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -36,055,887 | -77,198,766 | -1,575,968 | -1,727,883 |
| Free Cash Flow | — | — | -691,464 | -912,603 |